Nano drug delivery in intracellular bacterial infection treatments - 16/01/22
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
| pages | 13 |
| Iconographies | 6 |
| Vidéos | 0 |
| Autres | 0 |
Abstract |
The present work aimed to review the potential mechanisms used by macrophages to kill intracellular bacteria, their entrance to the cell, and mechanisms of escape of cellular immunity and applications of various nanoparticles. Since intracellular bacteria such as Mycobacterium and Brucella can survive in host cells and can resist the lethal power of macrophages, they can cause chronic disease or recur in 10–30% of cases in improved patients Nano drug-based therapeutics are promising tools for treating intracellular bacteria and preventing recurrence of the disease caused by these bacteria. In addition, among their unique features, we can mention the small size and the ability of these compounds to purposefully reach the target location.
Le texte complet de cet article est disponible en PDF.Highlights |
• | Nano drug-based therapeutics are promising tools for treating intracellular bacteria. |
• | In accordance to the bioavailability of the drug causes to prevent of the destruction of the drug. |
• | While reducing the side effects and toxicity associated with the drug, reduce the long course of treatment. |
• | By using of the nanoparticle could reduce the recurrence of the disease. |
Keywords : Intracellular bacteria, Mycobacterium, Brucella, Macrophages, Nano drug, Recurrence
Plan
Vol 146
Article 112609- février 2022 Retour au numéro
Article précédent
- Pulmonary artery targeted therapy in treatment of COVID-19 related ARDS. Literature review
- Oskar Puk, Aleksandra Nowacka, Klaudia Smulewicz, Katarzyna Mocna, Wiktor Bursiewicz, Natalia Kęsy, Justyna Kwiecień, Michał Wiciński
- AMPK signaling in diabetes mellitus, insulin resistance and diabetic complications: A pre-clinical and clinical investigation
- Maliheh Entezari, Danial Hashemi, Afshin Taheriazam, Amirhossein Zabolian, Shima Mohammadi, Farima Fakhri, Mehrdad Hashemi, Kiavash Hushmandi, Milad Ashrafizadeh, Ali Zarrabi, Yavuz Nuri Ertas, Sepideh Mirzaei, Saeed Samarghandian
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’achat d’article à l’unité est indisponible à l’heure actuelle.
Déjà abonné à cette revue ?